BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29415943)

  • 1. [Relationship between clinical features and somatic gene mutations in myelodysplastic syndrome].
    Hirasawa N; Sakata-Yanagimoto M; Nannya Y; Hattori K; Suehara Y; Kato T; Yokoyama Y; Kurita N; Obara N; Ogawa S; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2018; 59(1):80-83. PubMed ID: 29415943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
    Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
    Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis of MDS: morphology, chromosome abnormalities and genetic mutations].
    Hata T
    Rinsho Ketsueki; 2015 Oct; 56(10):1978-84. PubMed ID: 26458436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
    Fu B; Jaso JM; Sargent RL; Goswami M; Verstovsek S; Medeiros LJ; Wang SA
    Mod Pathol; 2014 May; 27(5):681-9. PubMed ID: 24186132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
    Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
    Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations.
    Nazha A; Sekeres MA
    Annu Rev Med; 2017 Jan; 68():127-137. PubMed ID: 27618752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unrelated HLA-matched donor marrow transplantation for one case of myelodysplastic syndrome].
    Gao CJ; Da WM; Zhang BL; Han XP; Zhu HY; Jin HJ; Jing Y; Huang WR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):378-80. PubMed ID: 15228672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
    Nazha A; Bejar R
    Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection].
    Yamamoto H; Hattori H; Takagi E; Morishita T; Ishikawa Y; Terakura S; Nishida T; Ito Y; Murata M; Kiyoi H
    Rinsho Ketsueki; 2018; 59(3):315-322. PubMed ID: 29618691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.